The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Open accessAbstract
Myc amplification may transcriptionally regulate immune inhibition-associated molecules such as CD47 and PD-L1 in a mouse model of T cell acute lymphoblastic leukemia (12).In addition, Kras G12D can cause an increase in expression of the inflammatory cytokine GM-CSF in a mouse model of pancreatic neoplasia (13).Loss of P53 function activates the JAK2-STAT3 signaling pathway and promotes pancreatic tumor growth (14), and mutant P53 prolongs NF-kB activation and increases colorectal tumor incidence in a mouse model (15).These studies reveal a general mechanistic connection between cancer driver mutation-related inflammation and cancer progression in different model systems.However, the link among cancer driver gene mutations, T cell immunity, and immunotherapy response has not been established in patients with cancer.Thus, we have attempted to explore whether cancer genetic driver mutation(s) are capable of directly driving cancer immune phenotype, contributing to IFN signature and T cell immunity, and affecting immunotherapy response in models and in patients with cancer.Given that the most recurrent cancer driver genetic mutations, including MYC, APC, TP53, and KRAS, have been examined, in this work we focused our studies on the cancer driver epigenetic mutations such as ARID1A mutations (16)(17)(18)(19).ARID1A belongs to the SWI/SNF complex and is a core member of the ATP-dependent polymorphic BRG/BRM-associated factor (BAF) chromatin remodeling unit.SWI/SNF complex mutations Whether mutations in cancer driver genes directly affect cancer immune phenotype and T cell immunity remains a standing question.ARID1A is a core member of the polymorphic BRG/BRM-associated factor chromatin remodeling complex.ARID1A mutations occur in human cancers and drive cancer development.Here, we studied the molecular, cellular, and clinical impact of ARID1A aberrations on cancer immunity.We demonstrated that ARID1A aberrations resulted in limited chromatin accessibility to IFN-responsive genes, impaired IFN gene expression, anemic T cell tumor infiltration, poor tumor immunity, and shortened host survival in many human cancer histologies and in murine cancer models.Impaired IFN signaling was associated with poor immunotherapy response.Mechanistically, ARID1A interacted with EZH2 via its carboxyl terminal and antagonized EZH2-mediated IFN responsiveness.Thus, the interaction between ARID1A and EZH2 defines cancer IFN responsiveness and immune evasion.Our work indicates that cancer epigenetic driver mutations can shape cancer immune phenotype and immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 4×
“POLE mutations (48) and PIK3CA mutations (16, 17, 49) frequently co-occur with ARID1A mutations (32, 48).”
BackgroundResultInfluentialMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Type-I and type-II IFN gene signatures correlate with clinical responses to cancer immunotherapy (4-7), biological antibody therapy, chemotherapy, and radiation therapy (8-10).”
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“4 Introduction Tumor infiltrating T cells are positively associated with patient survival in many types of human cancer (1-3).”
BackgroundZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 3×
“ARID1A mutations were also associated with poor survival in patients with hepatocellular carcinoma (Figure 8C), hepatobiliary cancer (Figure 8D), and pancreatic cancer (Figure 8E) (46) in the MSKCCIMPACT cohort.”
BackgroundResultInfluentialGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“We found a nearly 3-fold decrease in the clinical response rate of melanoma patients with ARID1A C-terminal mutations as compared to patients without C-terminal mutations (31, 41-43) (Figure 7E).”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 7×
“It has been proposed that high tumor mutation load may increase the probability of generating immunogenic neoantigens and be associated with enhanced immunotherapy response (31, 53).”
BackgroundInfluentialSelf-citationEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 1×
“GSK126 specifically inhibits EZH2 methyltransferase activity (39).”
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationMYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Self-citationGenomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249 · cited 2×
“However, it is important to determine the potential impact of other concurrent genetic alterations on these RCCC patient survival and therapeutic outcome.”
BackgroundSelf-citationThe chromatin accessibility landscape of primary human cancers
Corces, M. R., Granja, J. M., Shams, S., Louie, B. H., Seoane, J. A., Zhou, W., Silva, T. C., Groeneveld, C., Wong, C. K., Cho, S. W., et al. (2018) · Science · doi:10.1126/science.aav1898 · Cited by 1,230 · cited 2×
“In addition to the established tumor cell lines, we also examined ATAC-seq data in primary human melanoma and colon cancer tissues (37).”
BackgroundMethodEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 12×
“EZH2 mediates CXCL9 and CXCL10 repression in tumor cells through H3K27me3 (28).”
BackgroundInfluentialSelf-citationPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186 · cited 1×
“MC38 cells harbor a single-epitope mutation within Adpgk protein (ASMTNRELM → ASMTNMELM), with the neo-epitope presented in MHC-I H-2Db molecules (40).”
BackgroundIdentification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863 · cited 2×
“8 levels of IRF1 expression in wild type ARD1A tumors as compared to mutated ARID1A tumors (Supplementary Figure 1E), Th1-type chemokines (Supplementary Figure 1F-1H), infiltrating CD8+ T cell- and cytotoxic T cell effector genes, granzyme B and perforin (Supplementary Figure 1I-1K) in metastatic ovarian carcinomas wi…”
BackgroundSelf-citationRoh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · cited 1×
“It has been recently reported that PBRM1 deficiency is associated with increased T cell tumor infiltration in the mouse B16 melanoma model (61) and its mutations may correlate with increased therapeutic response to immune checkpoint blockade in patients with renal clear cell carcinoma (RCCC) (62).”
BackgroundOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 1×
“In addition, KrasG12D can cause an increase in inflammatory cytokine, GMCSF expression in a mouse model of pancreatic neoplasia (13).”
BackgroundThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577 · cited 1×
“Type-I and type-II IFN gene signatures correlate with clinical responses to cancer immunotherapy (4-7), biological antibody therapy, chemotherapy, and radiation therapy (8-10).”
BackgroundShen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
Self-citationMyc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Interferon-γ: teammate or opponent in the tumour microenvironment?
Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00566-3 · Cited by 582
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Targeting ARID1A mutations in cancer
Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186
Metadata
- Authors
- Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., Wei, S., Zhou, J., Li, G., Jing, X., Vatan, L., Zhao, L., Bitler, B., Zhang, R., Cho, K. R., Dou, Y., Kryczek, I., Chan, T. A., Huntsman, D., Chinnaiyan, A. M., & Zou, W.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-04-20
- Volume
- 130
- Issue
- 5
- Pages
- 2712-2726
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3004964052
- Cited by
- 191
- References
- 30
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.